Elsevier

Drug Discovery Today

Volume 6, Issue 20, 15 October 2001, Page 1040
Drug Discovery Today

Update
People

https://doi.org/10.1016/S1359-6446(01)02029-3Get rights and content

Section snippets

Mike Ratchford joins Argenta Discovery

Argenta Discovery (Dagenham, UK) has recently announced the appointment of Michael F. Ratchford as President of Argenta US. Ratchford joins the company from being Senior Vice-President of Business Development at Evotec OAI and gained key skills in deal-making while at Oxford Asymmetry International (OAI) before its merger with Evotec. He also previously set up his own custom chemical company, AJ Chemicals, which was later acquired by Catalytica Pharmaceuticals.

Anthony Baxter, CEO of Argenta

New Hybridon CEO

Stephen R. Seiler, the former Executive Vice-President of Planning Investment and Development at Elan Corporation (Dublin, Ireland), has recently been appointed as CEO of Hybridon (Cambridge, MA, USA) and will join the company's Board of Directors. Before joining Elan, he was Head of Pharmaceutical Investment Banking at Paribas (London, UK). At the time of Seiler's agreement to join the company, he purchased 510,000 shares of Hybridon common shares from the company for cash at market.

New CEO for Fujisawa Healthcare

Fujisawa Healthcare (FHI; Deerfield, IL, USA), a subsidiary of Fujisawa Pharmaceutical Co. (Osaka, Japan), has appointed Hideo Fukumoto to the position of President and CEO of FHI. He has been President of the company since April 2001, but now takes over the position of CEO from Noboru Maeda who is returning to Japan. Maeda will remain Chairman of the Board of FHI and Corporate Executive Vice-President at Fujisawa Pharmaceutical Co. Fukumoto has 30 years of experience at Fujisawa Pharmaceutical

Hans-Peter Hasler joins Bio

Hans-Peter Hasler has joined Biogen (Cambridge, MA, USA) as Executive Vice-President of Commercial Operations. He was previously at Wyeth-Ayerst Pharmaceuticals (St David's, PA, USA), where he was Senior Vice-President, Head of Global Strategic Marketing, Chair of the Commercial Council and a member of the Wyeth/AHP (American Home Products, Wyeth's parent company) Executive Committee. Before this, he has served as Managing Director of Wyeth Group, General Manager AHP/Wyeth in Switzerland and

Douglas Modlin moves to new microfluidics company

Douglas N. Modlin, former Vice-President of Instrumentation Technology Research and Development at Molecular Devices Corp., has recently joined the microfluidics company, Fluidigm Corp. (formerly Mycometrix; South San Francisco, CA, USA) as Vice-President of Research and Development. Modlin has previously held positions at a variety of different types of companies such as life science tool providers [e.g. LJL BioSystems (before its merge with Molecular Devices), Affymax and Affymetrix], and

New CEO at Psychiatric Genomics

Psychiatric Genomics (PGI; Gaithersburg, MA, USA) has appointed Richard E. Chipkin as their new CEO. Chipkin comes to the job from Schering-Plough Corp., where he worked for more than 20 years, holding positions in preclinical and clinical neuropharmacology research, as well as, most recently, in the Global Business Development Group. Alan Walton from Oxford Bioscience Partners and Chairman of the Board of PGI said, ‘Richard's extensive interdisciplinary experience in the pharmaceutical

Two key appointments at Myriad Pharmaceuticals

Edward A. Swabb has joined Myriad Pharmaceuticals (Salt Lake City, UT, USA; a subsidiary of Myriad Genetics) as Senior Vice-President and Head of Development of its subsidiary. In doing so, he leaves his current position of Executive Director of Clinical Research at Pharmacia Corporation (formerly G.D. Searle and Co., a division of Monsanto) where he directed the review of clinical safety data of Celebrex leading to its approval, and designed and implemented Phase II and III global studies of

People was written by Rebecca N. Lawrence

References (0)

Cited by (0)

People was written by Rebecca N. Lawrence

View full text